Mile High Labs Files Drug Master File for CBD Isolate
News related to:Mile High Labs · 1 min read
LOVELAND, Colo., Nov. 19, 2026 /CourierPR/ -- Mile High Labs, a global leader in hemp-derived cannabinoid ingredients, has filed a Drug Master File (DMF #044151) with the U.S. Food and Drug Administration for its CBD Isolate, a 98% cannabidiol isolate. The file was submitted on October 2, 2026. Companies developing drug products can reference DMF #044151 in their own FDA submissions through a Letter of Authorization from Mile High Labs.
The filing marks a significant milestone in Mile High Labs' ongoing advancement within the pharmaceutical channel. The company, which has been committed to high-quality hemp-derived cannabinoid ingredients for over 10 years, has invested in quality to bring its ingredients into highly regulated markets around the world.
Mile High Labs, based in Loveland, Colorado, offers a portfolio that includes CBD, CBG, CBN, and CBC isolates, distillates, and water-soluble formats. The company continues to expand its pharmaceutical capabilities and regulatory readiness, preparing for an FDA inspection and strengthening its ability to serve drug developers in the U.S. and abroad.
The file is expected to appear on FDA's public list of Drug Master Files in its next quarterly update.